LXEO vs. EDIT, VYGR, FATE, ITOS, CCCC, TSHA, OCGN, ALVO, ALLO, and REPL
Should you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), Taysha Gene Therapies (TSHA), Ocugen (OCGN), Alvotech (ALVO), Allogene Therapeutics (ALLO), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Lexeo Therapeutics (NASDAQ:LXEO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Lexeo Therapeutics presently has a consensus price target of $20.80, suggesting a potential upside of 53.17%. Editas Medicine has a consensus price target of $13.90, suggesting a potential upside of 151.81%. Given Editas Medicine's higher probable upside, analysts plainly believe Editas Medicine is more favorable than Lexeo Therapeutics.
Editas Medicine received 296 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.
In the previous week, Editas Medicine had 11 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 14 mentions for Editas Medicine and 3 mentions for Lexeo Therapeutics. Editas Medicine's average media sentiment score of 0.86 beat Lexeo Therapeutics' score of 0.05 indicating that Editas Medicine is being referred to more favorably in the news media.
Lexeo Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -239.36%. Editas Medicine's return on equity of -47.34% beat Lexeo Therapeutics' return on equity.
Lexeo Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.
60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Editas Medicine beats Lexeo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Lexeo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexeo Therapeutics Competitors List
Related Companies and Tools
